LifeMD shares rise 10.06% after-hours after expanding telehealth access to Novo Nordisk's Wegovy pill.

LifeMD surged 10.06% in after-hour trading following its announcement of expanded access to Novo Nordisk’s Wegovy (semaglutide) pill via its telehealth platform. The move, which includes cash-pay pricing starting at $149/month, deepens LifeMD’s collaboration with Novo Nordisk and positions the company to capitalize on the growing obesity care market by integrating FDA-approved GLP-1 therapies with virtual care and pharmacy fulfillment. This development aligns with bullish analyst sentiment, as firms like H.C. Wainwright and Lake Street have highlighted operational progress in LifeMD’s core telehealth and pharmacy model, even as revised revenue guidance and competitive pressures in weight management temper broader expectations. The after-hour rally reflects investor optimism over the company’s strategic focus on high-margin GLP-1 offerings and its ability to scale telehealth-based chronic care solutions.